Bendamustine and Pneumocystis Pneumonia: A Systematic Review

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2022 May 5

PMID 35509412

Authors

Atousa Hakamifard

Masoud Mardani

Mohammad Javad Nasiri

Tahereh Gholipur-Shahraki

Affiliations

Soon will be listed here.

Abstract

Background: Bendamustine, a bifunctional mechlorethamine alkylating agent, is used in the treatment of patients with hematologic malignancies. Myelosuppression and cytotoxic effect arises quite often after bendamustine treatment. To date, there have been no recommendations for routine chemoprophylaxis for pneumonia (PCP) in patients under treatment with this agent. The present systematic review aimed to evaluate the existing data on bendamustine effects on pneumocystis pneumonia.

Method: English papers were systematically reviewed using Web of Science, Embase, Google Scholar, PubMed, and Cochrane library. There was no time constraint for the paper search. The used keywords included "Pneumonia, Pneumocystis"or "Pneumocystis Pneumonia"or "Pneumocystis jirovecii" and "Bendamustine hydrochloride or Bendamustine. "Through our search, 113 papers were found, 26 of which were chosen following a review of the titles and abstracts; ultimately, 10 were included in the research.

Result: A total of 10 studies (out of 113 studies) were retrieved. The papers were classified into seven case reports, two clinical trials, and one retrospective analysis study. The case reports included 14 patients diagnosed with PCP after bendamustine administration between 2003 and 2019. The patients' mean age was with a range of 66.8. Non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma and mantle cell lymphoma) ( = 9, 60%), chronic lymphocytic leukemia ( = 4, 26.6%), and breast cancer ( = 2, 13.4%) were the most prevalent types of malignancy. Bendamustine, along with rituximab, were the most commonly prescribed chemotherapy regimens during the treatments. Finally, the mortality rate among the patients whose results were reported ( = 9) was 44.44% ( = 4).

Conclusion: The present review described PCP infection in patients with malignancies after the treatment with bendamustine, a chemotherapeutic agent associated with lymphopenia. Further research is required to determine the PCP risk in patients with bendamustine treatment and identify individuals who may benefit from prophylaxis.

Citing Articles

Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.

Alderuccio J, Lossos I Expert Rev Hematol. 2023; 16(5):333-348.

PMID: 37086394 PMC: 10183153. DOI: 10.1080/17474086.2023.2206557.

Myocardial Infarction As the Initial Presentation of Rituximab-Induced Interstitial Lung Disease: A Case Report.

Mahmoud M, Khan A, El Kortbi K, Wang H, Wang J Cureus. 2022; 14(8):e28179.

PMID: 36148180 PMC: 9482808. DOI: 10.7759/cureus.28179.

Bendamustine and pneumocystis pneumonia: A systematic review.

Hakamifard A, Mardani M, Nasiri M, Gholipur-Shahraki T Health Sci Rep. 2022; 5(3):e610.

PMID: 35509412 PMC: 9059183. DOI: 10.1002/hsr2.610.

References

Cheson B, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E . Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update. Leuk Lymphoma. 2015; 57(4):766-82. PMC: 4840280. DOI: 10.3109/10428194.2015.1099647. View

Su Y, Lu J, Perng C, Chang F . Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect. 2009; 41(6):478-82. View

Morris A, Norris K . Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev. 2012; 25(2):297-317. PMC: 3346301. DOI: 10.1128/CMR.00013-12. View

Green H, Paul M, Vidal L, Leibovici L . Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82(9):1052-9. DOI: 10.4065/82.9.1052. View

Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P . ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016; 71(9):2405-13. DOI: 10.1093/jac/dkw158. View

Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U . [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study]. Pneumologie. 1998; 52(10):570-3. View

Limper A, Knox K, Sarosi G, Ampel N, Bennett J, Catanzaro A . An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011; 183(1):96-128. DOI: 10.1164/rccm.2008-740ST. View

Abkur T, Saeed M, Ahmed S, McArthur R, Leahy M, OLeary H . Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol. Clin Case Rep. 2015; 3(4):255-9. PMC: 4405313. DOI: 10.1002/ccr3.195. View

Classen A, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff L . Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and.... Ann Hematol. 2021; 100(6):1603-1620. PMC: 8116237. DOI: 10.1007/s00277-021-04452-9. View

10.

Bollee G, Sarfati C, Thiery G, Bergeron A, de Miranda S, Menotti J . Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007; 132(4):1305-10. DOI: 10.1378/chest.07-0223. View

11.

Sarlo K, Dixon B, Ni A, Straus D . Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody. Leuk Lymphoma. 2019; 61(2):364-369. DOI: 10.1080/10428194.2019.1666378. View

12.

Klippstein A, Schneider C, Sayer H, Hoffken K . Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol. 2003; 129(5):316-9. DOI: 10.1007/s00432-003-0441-y. View

13.

Rodriguez M, Fishman J . Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004; 17(4):770-82, table of contents. PMC: 523555. DOI: 10.1128/CMR.17.4.770-782.2004. View

14.

Reinbolt R, Alam S, Layman R, Shapiro C, Lustberg M . Pneumocystis jiroveci Pneumonia in an Atypical Host. Clin Breast Cancer. 2011; 12(2):138-41. PMC: 3498486. DOI: 10.1016/j.clbc.2011.10.003. View

15.

Carter S, Bernstein S, Friedberg J, Barr P . Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011; 35(11):e223-4. DOI: 10.1016/j.leukres.2011.07.014. View

16.

White P, Backx M, Barnes R . Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017; 15(5):435-447. DOI: 10.1080/14787210.2017.1305887. View

17.

Cheson B, Friedberg J, Kahl B, van der Jagt R, Tremmel L . Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010; 10(6):452-7. DOI: 10.3816/CLML.2010.n.079. View

18.

Kath R, Blumenstengel K, Fricke H, Hoffken K . Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001; 127(1):48-54. DOI: 10.1007/s004320000180. View

19.

Layman R, Ruppert A, Lynn M, Mrozek E, Ramaswamy B, Lustberg M . Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol. 2013; 71(5):1183-90. PMC: 3710373. DOI: 10.1007/s00280-013-2112-2. View

20.

Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J . Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016; 128(14):1814-1820. DOI: 10.1182/blood-2016-03-704023. View